Novel Compound GPX-150 Shows Promise in Soft Tissue Sarcoma

Danielle Bucco
Published Online: Wednesday, Feb 22, 2017

Brian Van Tine, MD, PhD

Brian Van Tine, MD, PhD

The investigational compound 5-imino-13-deoxydoxorubicin (GPX-150) was active and well tolerated in patients with metastatic and nonresectable soft tissue sarcoma (STS), according to data from a single-arm phase II study presented at the 2016 Connective Tissue Oncology Society Annual Meeting.

Among 21 evaluable patients with locally advanced and/or metastatic intermediate or high-grade STS, GPX-150 induced a clinical benefit rate (CBR) of 43%. The CBR included 1 partial response and 8 patients with stable disease.

GPX-150 was well tolerated, detecting no irreversible cardiotoxicity and no grade 3 or 4 toxicities besides hematological toxicity. The toxicities included 2 patients (10%) with grade 3/4 neutropenia, 1 patient (5%) with grade 3 febrile neutropenia, and 3 patients (14%) with grade 3 anemia. The toxicities that were less than grade 3 included mucositis, nausea, vomiting, alopecia, and fatigue.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Optimizing Treatment and Management of Soft Tissue Sarcoma in Community OncologyNov 30, 20171.5
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Publication Bottom Border
Border Publication
x